Results 151 to 160 of about 13,822,676 (240)

Pergamon Acropolis Model

, 1950
Detail, Temple of Dionysus at lowest point, center, Temple of Trajan (2nd century CE) in courtyard, theater, lower right; Pergamon was an ancient Greek city in Asia Minor (now Bergama, Turkey), later part of the Roman Empire.
unknown (German model maker)
core  

Covalent fluorescent probes for 2‐arachidonoylglycerol metabolic pathways

British Journal of Pharmacology, EarlyView.
Abstract Covalent fluorescent probes have emerged as versatile chemical tools to visualise active enzymes in complex biological systems. When tailored for specific applications, ranging from activity‐based protein profiling for drug development to high spatiotemporal resolution imaging of enzymatic activities, these probes provide unique insights into ...
Nick D. F. Puijmbroeck, Mario van der Stelt   +1 more
wiley   +1 more source

Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt

British Journal of Pharmacology, EarlyView.
Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown, Alan Armstrong, David J. Mann   +2 more
wiley   +1 more source

Proposal of pharmacophore model for HIV reverse transcriptase inhibitors: Combined mutational effect analysis, molecular dynamics, molecular docking and pharmacophore modeling study. [PDF]

Int J Immunopathol Pharmacol
Annan A, Raiss N, Lemrabet S, Elomari N, Elmir EH, Filali-Maltouf A, Medraoui L, Oumzil H.   +7 more
europepmc   +1 more source

The discovery and development of ensifentrine: A novel inhaled dual PDE3/4 inhibitor having ‘bifunctional’ bronchodilator and anti‐inflammatory activity

British Journal of Pharmacology, EarlyView.
Abstract Ensifentrine (formerly called RPL 554) is a novel, first in class, inhaled bifunctional dual PDE3/4 inhibitor for the treatment of chronic respiratory diseases. Ensifentrine exhibits both bronchodilation via PDE3 inhibition and anti‐inflammatory activity via PDE4 inhibition.
Clive Page
wiley   +1 more source

A Pharmacophore Model for SARS-CoV-2 3CLpro Small Molecule Inhibitors and in Vitro Experimental Validation of Computationally Screened Inhibitors

, 2021
Glaab E, Manoharan GB, Abankwa D.
europepmc   +1 more source

Scale model of Sainte-Chapelle

, 1947
Model, detail on the north wall, originally the staircase (the Grands Degres); The Galerie des Moulages (cast collection) not only contains 19th plaster casts, but also scale models of buildings done by artisans on staff at the museum.
unknown (French model maker)
core  

Selective modulation of NaV channel gating counteracts aberrant hyperexcitability and rescues motor function and survival in a model of spinal muscular atrophy

British Journal of Pharmacology, EarlyView.
Background and Purpose Spinal muscular atrophy (SMA) is a motor neuron disease caused by SMN1 gene loss, leading to reduced survival motor neuron (SMN) protein and progressive motor neuron degeneration. Although SMN‐restoring therapies improve outcomes, residual disease burden and non‐curative efficacy underscore the need for complementary treatments ...
Fernanda C. Cardoso, Jessica A. I. Muller, Yougang Zhang, Jean Giacomotto   +3 more
wiley   +1 more source

Identification of coumarin derivatives targeting acetylcholinesterase for Alzheimer's disease by field-based 3D-QSAR, pharmacophore model-based virtual screening, molecular docking, MM/GBSA, ADME and MD Simulation study. [PDF]

Curr Res Struct Biol
Saha B, Das A, Jangid K, Kumar A, Kumar V, Jaitak V.   +5 more
europepmc   +1 more source

Triple-negative breast cancer suppressive activities, antioxidants and pharmacophore model of new acylated rhamnopyranoses from Premna odorata. [PDF]

RSC Adv, 2020
Elmaidomy AH, Mohammed R, Owis AI, Hetta MH, AboulMagd AM, Siddique AB, Abdelmohsen UR, Rateb ME, El Sayed KA, Hassan HM.   +9 more
europepmc   +1 more source